Adoptive cell therapy with autologous tumor-infiltrating lymphocytes and high-dose interleukin-2 for metastatic melanoma: The surgeon's perspective

Zippel,Douglas  B.; Besser,Michal; Shapira,Roni; Ben-Nun,Alon; Goitein,David; Davidson,Tima; Treves,Abraham   J.; Markel,Gal; Schachter,Jacob; Papa,Moshe  Z.

doi:10.3892/etm.2012.498

May 2012 Volume 3 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

May 2012 Volume 3 Issue 5

Full Size Image

Article

Adoptive cell therapy with autologous tumor-infiltrating lymphocytes and high-dose interleukin-2 for metastatic melanoma: The surgeon's perspective

Authors:
- Douglas B. Zippel
- Michal Besser
- Roni Shapira
- Alon Ben-Nun
- David Goitein
- Tima Davidson
- Abraham J. Treves
- Gal Markel
- Jacob Schachter
- Moshe Z. Papa
View Affiliations / Copyright

Affiliations: Department of Surgical Oncology, Chaim Sheba Medical Center, Tel Hashomer, Israel, Sheba Cancer Research Center, Chaim Sheba Medical Center, Tel Hashomer, Israel, Department of Oncology, Chaim Sheba Medical Center, Tel Hashomer, Israel, Department of Thoracic Surgery, Chaim Sheba Medical Center, Tel Hashomer, Israel, Department of Nuclear Medicine, Chaim Sheba Medical Center, Tel Hashomer, Israel
Pages: 898-902
|
Published online on: February 28, 2012

https://doi.org/10.3892/etm.2012.498
Expand metrics +

Abstract

Tumor-infiltrating lymphocytes (TILs) are produced by resecting tumor tissue and growing and expanding ex vivo large quantities of autologous T cells. Once the TILs are ready for infusion, the patient undergoes a non-myeloablative lympho-depleting course of chemotherapy and subsequent TIL infusion with high-dose bolus IL-2. This study reviews the surgical experience of the TIL program at the Chaim Sheba Cancer Research Center in Israel. Eligible patients underwent surgical consultation to determine what tumorectomy would be beneficial for harvesting appropriate tissue. Factors involved in the decision included tumor mass size, location and morbidity of the procedure. Between January 2006 and May 2010, 44 patients underwent 47 procedures of adoptive transfer of TILs. Three patients underwent the procedure twice for recurrence after initial good responses, including an additional surgical procedure to produce fresh tumor. Thirty‑seven excisions were with general anesthesia and 10 were with local anesthesia. Of the 37 general anesthesia procedures, 27 were open procedures involving a thoracotomy, a laparotomy or dissection of a major lymph node basin. Ten used minimally invasive techniques such as thorascopy or laparoscopy. Tumorectomy sites included 18 lymph node metastasis, 13 subcutaneous nodules, 11 lung specimens and 5 abdominal visceral metastasis including 2 liver lesions. Surgical mortality and major morbidity was 0%. Minor morbidity included only wound complications. Maximal number of TILs were derived from lymph node specimens, while liver metastasis procured the fewest TILs. Adoptive cell transfer technology affords a maximal tumor response with minimal surgical morbidity in metastatic patients.

View Figures

View References

1.	Khan MA, Andrews S, Ismail-Khan R, et al: Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database. Cancer Control. 13:211–217. 2006.PubMed/NCBI
2.	Tarhini AA and Agarwala SS: Cutaneous melanoma: available therapy for metastatic disease. Dermatol Ther. 19:19–25. 2006. View Article : Google Scholar : PubMed/NCBI
3.	Tsao H, Atkins MB and Sober AJ: Management of cutaneous melanoma. N Engl J Med. 351:998–1012. 2004. View Article : Google Scholar
4.	Rosenberg SA and Dudley ME: Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol. 21:233–240. 2009. View Article : Google Scholar : PubMed/NCBI
5.	Rosenberg SA, Restifo NP, Yang JC, et al: Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 8:299–308. 2008. View Article : Google Scholar : PubMed/NCBI
6.	Dudley ME and Rosenberg SA: Adoptive cell transfer therapy. Semin Oncol. 34:524–531. 2007. View Article : Google Scholar
7.	Dudley ME, Yang JC, Sherry R, et al: Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 26:5233–5239. 2008. View Article : Google Scholar
8.	Besser MJ, Shapira-Frommer R, Treves AJ, et al: Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res. 16:2646–2655. 2010. View Article : Google Scholar
9.	Itzhaki O, Hovav E, Ziporen Y, et al: Establishment and large scale expansion of minimally cultured ‘young’ tumor infiltrating lymphocytes for adoptive transfer therapy. J Immunother. 34:212–220. 2011.PubMed/NCBI
10.	Dutcher J: Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma. Oncology (Williston Park). 16:4–10. 2002.PubMed/NCBI
11.	Atkins MB, Hsu J, Lee S, et al: Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 26:5748–5754. 2008.
12.	Dudley ME, Wunderlich JR, Shelton TE, et al: Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother. 26:332–342. 2003. View Article : Google Scholar : PubMed/NCBI
13.	Besser MJ, Shapira-Frommer R, Treves AJ, et al: Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients. J Immunother. 32:415–423. 2009. View Article : Google Scholar
14.	Tran KQ, Zhou J, Durflinger KH, et al: Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother. 31:742–751. 2008. View Article : Google Scholar : PubMed/NCBI
15.	Schallmach E, Sareli R, Besser MJ, et al: Collection of large-scale expanded lymphocyte cultures for adoptive immunotherapy using a COBE Spectra apheresis machine. J Immunother. 31:563–568. 2008. View Article : Google Scholar : PubMed/NCBI
16.	Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar
17.	Dudley ME, Wunderlich JR, Yang JC, et al: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory meta-static melanoma. J Clin Oncol. 23:2346–2357. 2005. View Article : Google Scholar : PubMed/NCBI
18.	Ripley RT, Davis JL, Klapper JA, et al: Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy. Ann Surg Oncol. 17:163–170. 2010. View Article : Google Scholar : PubMed/NCBI
19.	Karlsson M, Marits P, Dahl K, et al: Pilot study of sentinel-node-based adoptive immunotherapy in advanced colorectal cancer. Ann Surg Oncol. 17:1747–1757. 2010. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Adoptive cell therapy with autologous tumor-infiltrating lymphocytes and high-dose interleukin-2 for metastatic melanoma: The surgeon's perspective

This article is mentioned in:

Abstract

Related Articles